Clinical trials: Tirzepatide
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased…
- Trial name
- SURMOUNT-1 (NCT07481747)
- Testing
- Tirzepatide, Reduced-calorie diet
- Where
- China
- Volunteers
- 2,539 people
- Sponsor
- Hudson Biotech
Type 2 Diabetes, Obesity
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin.
- Trial name
- NCT06037252
- Testing
- Tirzepatide
- Where
- 40 sites in United States, Argentina and 2 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight, Obesity
Genetic, Microbiological and Behavioral Factors in Obesity
This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity.
- Conditions
- Obesity & Overweight, Obesity, Genetics
- Trial name
- OPTIMIZE-GEN (NCT07650149)
- Testing
- genetic polymorphism, gut microbiome
- Where
- 2 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Jan Kochanowski University
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Trial name
- OPTIMAL (NCT07058155)
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
Aging, LONGEVITY 1
Tirzepatide to Slow Biological Aging
This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will…
- Trial name
- NCT07220473
- Testing
- Zepbound
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Obesity, Menopause Hot Flashes
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
- Trial name
- NCT07218445
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney, Obesity
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can…
- Trial name
- NCT06582875
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Colorado, Denver
Ulcerative Colitis, Obesity or Overweight
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and…
- Trial name
- COMMIT-UC (NCT06937086)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 187 sites in United States, Austria and 21 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2…
- Trial name
- NCT06643728
- Testing
- Bimagrumab, Tirzepatide
- Where
- 12 sites in United States
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Obesity
Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
This is a prospective, pragmatic, 21 month, single-center, randomized, 2-phased, open-label, parallel-group trial comparing the use of enhanced lifestyle changes (ELC) in two different therapy: sequential vs continuation of AOM.
- Trial name
- STAY-LEAN (NCT06854614)
- Testing
- Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- The Cleveland Clinic
Cannabis Use Disorder
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
- Trial name
- NCT07468552
- Testing
- Tirzepatide
- Volunteers
- 100 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Obesity & Overweight, Cardiometabolic Health Indicators
Tirzepatide Impact Assessment Study
This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body.
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders
- Trial name
- TIA (NCT07740291)
- Testing
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disease, often compounded by obesity, that leads to serious long-term health complications.
- Trial name
- NCT07728318
- Testing
- Tirzepatide + Standard Therapy (Intervention Group), Standard Oral Antidiabetic Drugs (OADs)
- Volunteers
- 52 people
- Sponsor
- Akhtar Saeed Medical and Dental College
Type2 Diabetes Mellitus, Atherosclerotic Cardiovascular Disease
Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07203677
- Testing
- Initiation of tirzepatide, Initiation of sitagliptin
- Where
- United States
- Volunteers
- 49,065 people
- Sponsor
- Brigham and Women's Hospital
Obesity and Obesity-related Medical Conditions
Efficacy and Safety of Tirzepatide for Weight Management
The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes.
- Trial name
- NCT06918405
- Testing
- Tirzepatide
- Where
- Bangladesh
- Volunteers
- 440 people
- Sponsor
- Chittagong Medical College
Obesity, Metabolic Disease
Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with double blind treatment to evaluate the effects of a drug called tirzepatide in combination with an innovative, culturally-appropriate…
- Trial name
- TRZ (NCT06009653)
- Testing
- Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Tirzepatide
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Obesity &Amp; Overweight, Digestive Disorders
Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment
Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role.
- Trial name
- PROBIO-GLP1 (NCT07213323)
- Testing
- Probiotics (Natural product)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company